Understanding how certain immune cells affect T cell function in kidney cancer treatment
Official title: Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma
Funded at Sloan-Kettering Inst Can Research · NIH-11051217 · Data updated 2026-11-12
This study is looking at how certain immune cells called tumor-associated macrophages affect kidney cancer and how they might change the way your body responds to treatment, with the goal of finding better ways to help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 8, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $465,743 |
| NIH project number | 5R01CA258886-05 |
| Project ID | NIH-11051217 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced clear cell renal cell carcinoma who are undergoing or have undergone treatment.
✕Less likely to help
Patients with early-stage kidney cancer or those not diagnosed with clear cell renal cell carcinoma may not benefit from this research.
What this research studies
This research investigates the role of tumor-associated macrophages (TAMs) in clear cell renal cell carcinoma (ccRCC), a common and aggressive form of kidney cancer. The study aims to identify specific subpopulations of TAMs that influence T cell behavior and therapeutic responses. By analyzing immune cell populations in different patient tumor samples, the researchers hope to uncover mechanisms of treatment resistance and develop strategies to enhance the effectiveness of existing therapies. Patients may benefit from insights that could lead to more targeted and effective treatment options.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with advanced kidney cancer, potentially overcoming resistance to current therapies.
How similar studies have gone: Previous research has shown promising results in targeting immune cells to enhance cancer treatment, indicating that this approach may be viable.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Hakimi, Abraham Ari — Sloan-Kettering Inst Can Research
- Study coordinator: Hakimi, Abraham Ari
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.